DOCSLIB.ORG

De Novo Mutations in Histone Modifying Genes in Congenital Heart Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
De Novo Mutations in Histone Modifying Genes in Congenital Heart Disease De novo mutations in histone modifying genes in congenital heart disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Zaidi, S., M. Choi, H. Wakimoto, L. Ma, J. Jiang, J. D. Overton, A. Romano-Adesman, et al. 2013. “De novo mutations in histone modifying genes in congenital heart disease.” Nature 498 (7453): 220-223. doi:10.1038/nature12141. http://dx.doi.org/10.1038/ nature12141. Published Version doi:10.1038/nature12141 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879354 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2013 December 13. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nature. 2013 June 13; 498(7453): 220–223. doi:10.1038/nature12141. De novo mutations in histone modifying genes in congenital heart disease Samir Zaidi1,2,*, Murim Choi1,2,*, Hiroko Wakimoto3, Lijiang Ma4, Jianming Jiang3,5, John D. Overton1,6,7, Angela Romano-Adesman8, Robert D. Bjornson7,9, Roger E. Breitbart10, Kerry K. Brown3, Nicholas J. Carriero7,9, Yee Him Cheung11, John Deanfield12, Steve DePalma3, Khalid A. Fakhro1,2, Joseph Glessner13, Hakon Hakonarson13,14, Michael Italia15, Jonathan R. Kaltman16, Juan Kaski12, Richard Kim17, Jennie K. Kline18, Teresa Lee4, Jeremy Leipzig15, Alexander Lopez1,6,7, Shrikant M. Mane1,6,7, Laura E. Mitchell19, Jane W. Newburger10, Michael Parfenov3, Itsik Pe'er20, George Porter21, Amy Roberts10, Ravi Sachidanandam22, Stephan J. Sanders1,23, Howard S. Seiden24, Mathew W. State1,23, Sailakshmi Subramanian22, Irina R. Tikhonova1,6,7, Wei Wang15,25, Dorothy Warburton4,26, Peter S. White14,15, Ismee A. Williams4, Hongyu Zhao1,27, Jonathan G. Seidman3, Martina Brueckner1,28,**, Wendy K. Chung4,30,**, Bruce D. Gelb22,24,31,**, Elizabeth Goldmuntz14,**, Christine E. Seidman3,5,32,**, and Richard P. Lifton1,2,6,7,33,** 1Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510, USA 2Howard Hughes Medical Institute, Yale University, CT, 06510, USA 3Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA 4Department of Pediatrics, Columbia University Medical Center, New York, NY, 10032, USA 5Howard Hughes Medical Institute, Harvard University, Boston, MA, 02115, USA 6Yale Center for Mendelian Genomics, New Haven, CT 06510, USA 7Yale Center for Genome Analysis, Yale University, New Haven, CT, 06511, USA 8Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, NY, 11040, USA 9Department of Computer Science, Yale University, New Haven, CT, 06511, USA 10Department of Cardiology, Children's Hospital Boston, Boston, MA, 02115, USA Correspondence to R.P.L ([email protected]).. *These authors contributed equally **These authors contributed equally Supplementary Information is linked to online version of the paper at www.nature.com/nature Author Contributions. Study design: M.B., W.K.C., B.D.G., E.G., H.H, J.R.K., R.P.L., L.E.M., J.G.S, C.E.S., D.W., P.S.W.; Cohort ascertainment, phenotypic characterization, and recruitment: R.E.B., M.B., W.K.C., J.D., B.D.G., E.G., J.K., R.K., T.L., J.W.N, G.P., A.R.A., H.S.S., C.E.S, I.A.W.; Informatics/data management: R.D.B., R.E.B, N.J.C., M.C., S.D., J.G., H.H., M.J.I., J.L., A.L., S.M.M., J.D.O., M.P., A.E.R., J.G.S., W.W., P.S.W, S.Z.; Exome sequencing production: J.D.O., A.L., R.P.L., S.M.M., M.W.S., I.R.T.; De novo mutation validation: W.K.C, L.M.; Exome sequencing analysis: K.K.B., Y.H.C., M.C., S.D., K.A.F., J.G., J.K.K., R.P.L., I.P., R.S., S.J.S., J.G.S., C.E.S., S.S., W.W., S.Z.; RNA sequence production/analysis: J.J., M.P., C.E.S., J.G.S, H.W.; Statistical analysis: M.C., R.P.L., I.P., A.R., C.E.S, J.G.S, S.Z., H.Z.; Writing of manuscript: M.B., M.C., W.K.C., B.D.G., E.G., J.R.K., R.P.L., C.E.S., S.Z. Author Information mRNA available at NCBI under accession IDs listed in Table S4; mutation data is available at dbSNP under batch accession 1059065. Reprints and permissions information is available at www.nature.com/reprints. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI. The authors declare no competing financial interests; details accompany the full-text HTML version of the paper at www.nature.com/nature. Zaidi et al. Page 2 11Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, 10032, USA NIH-PA Author Manuscript12 NIH-PA Author ManuscriptDepartment of Cardiology, NIH-PA Author Manuscript University College London, Great Ormond St Hospital, London, WC1N 3JH, UK 13Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA 14Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA 15The Center for Biomedical Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA 16National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA 17Section of Cardiothoracic Surgery, University of Southern California Keck School of Medicine, Los Angeles, CA, 90089, USA 18Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, 10032, USA 19Division of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, Texas, 77030, USA 20Department of Computer Science, Columbia University, New York, NY, 10032, USA 21Department of Pediatrics, University of Rochester Medical Center, The School of Medicine and Dentistry, Rochester, NY, 14611, USA 22Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA 23Program on Neurogenetics, Child Study Center, Department of Psychiatry, Yale University, New Haven, CT, 06510, USA 24Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA 25Department of Computer Science, New Jersey Institute of Technology, Newark, NJ, 07102, USA 26Department of Pathology, Columbia University Medical Center, New York, NY, 10032, USA 27Department of Biostatistics, Yale School of Public Health, New Haven, CT, 06510, USA 28Department of Pediatrics Yale University School of Medicine, New Haven, CT, 06510, USA 29Division of Cardiology, The Children's Hospital of Philadelphia, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA 30Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA 31The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA 32Cardiovascular Division, Brigham & Women's Hospital, Harvard University, Boston, MA, 02115, USA 33Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA Nature. Author manuscript; available in PMC 2013 December 13. Zaidi et al. Page 3 Abstract Congenital heart disease (CHD) is the most frequent birth defect, affecting 0.8% of live births1. NIH-PA Author Manuscript NIH-PA Author ManuscriptMany cases occur NIH-PA Author Manuscript sporadically and impair reproductive fitness, suggesting a role for de novo mutations. By analysis of exome sequencing of parent-offspring trios, we compared the incidence of de novo mutations in 362 severe CHD cases and 264 controls. CHD cases showed a significant excess of protein-altering de novo mutations in genes expressed in the developing heart, with an odds ratio of 7.5 for damaging mutations. Similar odds ratios were seen across major classes of severe CHD. We found a marked excess of de novo mutations in genes involved in production, removal or reading of H3K4 methylation (H3K4me), or ubiquitination of H2BK120, which is required for H3K4 methylation2–4. There were also two de novo mutations in SMAD2; SMAD2 signaling in the embryonic left-right organizer induces demethylation of H3K27me5. H3K4me and H3K27me mark `poised' promoters and enhancers that regulate expression of key developmental genes6. These findings implicate de novo point mutations in several hundred genes that collectively contribute to ~10% of severe CHD. From more than 5000 probands enrolled in the Congenital Heart Disease Genetic Network Study of the National Heart Lung and Blood Institute Pediatric Cardiac Genomics Consortium7, we selected 362 parent-offspring trios comprising a child (proband) with severe CHD and no first-degree relative with identified structural heart disease. Probands with an established genetic diagnosis were excluded. There were 154 probands with conotruncal defects, 132 with left ventricular obstruction, 70 with heterotaxy and six with other diagnoses (Supplementary Table 1). Genomic DNA samples from trios underwent exome sequencing (see Methods)8. Targeted bases in each sample were sequenced a mean of 107 times by independent reads with 96.0% read eight or more times. In parallel, 264 trios comprising unaffected siblings of autism cases and their unaffected parents (Supplementary Table 1) were sequenced in the same facility using the same protocol and were analyzed as a control group9 (Supplementary Table 2, Supplementary Figure 1). Family relationships were confirmed from sequence data in all trios. High probability de novo variants in probands were identified using a Bayesian quality score (QS; see Methods). Sanger sequencing of 181 putative de novo mutations across the QS spectrum demonstrated strong correlation of confirmation with QS (R2 = 0.89), with 100% confirmation of 90 calls with QS > 50 (Supplementary Table 3, Supplementary Figure 2).
Load more

Recommended publications
  • DNA Aneuploidy in Malignant Salivary Gland
    Brazilian Dental Journal (2017) 28(2): 148-151 ISSN 0103-6440 http://dx.doi.org/10.1590/0103-6440201701018 1Department of Pathology, DNA Aneuploidy in Malignant Salivary Biological Sciences Institute, UFMG - Universidade Federal de Minas Gland Neoplasms is Independent Gerais, Belo Horizonte, MG, Brazil 2Division of Salivary and Mucosal of USP44 Protein Expression Research, Oral Pathology, King’s College London Dental Institute, London, UK 3Department of Oral Pathology and Medicine, Dental School, UFMG - Universidade Federal de Minas Vanessa Fátima Bernardes1, Edward W Odell2, Ricardo Santiago Gomez3 Gerais, Belo Horizonte, MG, Brazil Carolina Cavalieri Gomes1 Correspondence: Vanessa F. Bernardes, Av. Presidente Antônio Carlos 6627, Pampulha, 31270-901 Belo Horizonte, MG, Brasil. Tel: +55-31-3409-2477 e-mail: [email protected] Chromosomal instability, leading to aneuploidy, is one of the hallmarks of human cancers. USP44 (ubiquitin specific peptidase 44) is an important molecule that plays a regulatory role in the mitotic checkpoint and USP44 loss causes chromosome mis- segregation, aneuploidy and tumorigenesis in vivo. In this study, it was investigated the Key Words: ubiquitin specific immunoexpression of USP44 in 28 malignant salivary gland neoplasms and associated the protease, mucoepidermoid results with DNA ploidy status assessed by image cytometry. USP44 protein was widely carcinoma, adenoid cystic expressed in most of the tumor samples and no clear association could be established carcinoma, polymorphous low between its expression and DNA ploidy status or tumor size. On this basis, it may be grade adenocarcinoma, carcinoma concluded that the aneuploidy of the salivary gland cancers included in this study was ex-pleomorphic adenoma, not driven by loss of USP44 protein expression.
    [Show full text]
  • Pan-Cancer Analysis of Homozygous Deletions in Primary Tumours Uncovers Rare Tumour Suppressors
    Corrected: Author correction; Corrected: Author correction ARTICLE DOI: 10.1038/s41467-017-01355-0 OPEN Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors Jiqiu Cheng1,2, Jonas Demeulemeester 3,4, David C. Wedge5,6, Hans Kristian M. Vollan2,3, Jason J. Pitt7,8, Hege G. Russnes2,9, Bina P. Pandey1, Gro Nilsen10, Silje Nord2, Graham R. Bignell5, Kevin P. White7,11,12,13, Anne-Lise Børresen-Dale2, Peter J. Campbell5, Vessela N. Kristensen2, Michael R. Stratton5, Ole Christian Lingjærde 10, Yves Moreau1 & Peter Van Loo 3,4 1234567890 Homozygous deletions are rare in cancers and often target tumour suppressor genes. Here, we build a compendium of 2218 primary tumours across 12 human cancer types and sys- tematically screen for homozygous deletions, aiming to identify rare tumour suppressors. Our analysis defines 96 genomic regions recurrently targeted by homozygous deletions. These recurrent homozygous deletions occur either over tumour suppressors or over fragile sites, regions of increased genomic instability. We construct a statistical model that separates fragile sites from regions showing signatures of positive selection for homozygous deletions and identify candidate tumour suppressors within those regions. We find 16 established tumour suppressors and propose 27 candidate tumour suppressors. Several of these genes (including MGMT, RAD17, and USP44) show prior evidence of a tumour suppressive function. Other candidate tumour suppressors, such as MAFTRR, KIAA1551, and IGF2BP2, are novel. Our study demonstrates how rare tumour suppressors can be identified through copy number meta-analysis. 1 Department of Electrical Engineering (ESAT) and iMinds Future Health Department, University of Leuven, Kasteelpark Arenberg 10, B-3001 Leuven, Belgium.
    [Show full text]
  • A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
    Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context.
    [Show full text]
  • Novel Genetic Variants of Sporadic Atrial Septal Defect (ASD)
    CLINICAL RESEARCH e-ISSN 1643-3750 © Med Sci Monit, 2018; 24: 1340-1358 DOI: 10.12659/MSM.908923 Received: 2018.01.11 Accepted: 2018.02.08 Novel Genetic Variants of Sporadic Atrial Septal Published: 2018.03.05 Defect (ASD) in a Chinese Population Identified by Whole-Exome Sequencing (WES) Authors’ Contribution: ABCDEF 1,2,3 Yong Liu* 1 Department of Cardiovascular Surgery, Yan’an Affiliated Hospital of Kunming Study Design A A 1,2 Yu Cao* Medical University, Kunming, Yunnan, P.R. China Data Collection B 2 Department of Cardiovascular Surgery, The First Peoples’ Hospital of Yunnan Statistical Analysis C G 1,3 Yaxiong Li* Province, Kunming, Yunnan, P.R. China Data Interpretation D E 4 Dongyun Lei* 3 Key Laboratory of Cardiovascular Disease of Yunnan Province, Kunming, Yunnan, Manuscript Preparation E E 1,3 Lin Li P.R. China. Literature Search F 4 The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, Funds Collection G G 1,3 Zong Liu Hou P.R. China F 1,3 Shen Han G 1 Mingyao Meng C 1 Jianlin Shi G 1,3 Yayong Zhang B 1,3 Yi Wang B 1 Zhaoyi Niu G 1 Yanhua Xie B 1 Benshan Xiao B 1 Yuanfei Wang C 1 Xiao Li F 1 Lirong Yang ACDE 1,3 Wenju Wang AG 2 Lihong Jiang * Joint first authors; Yong Liu, Yu Cao, Yaxiong Li, Dongyun Lei Corresponding Authors: Lihong Jiang, e-mail: [email protected], Wenju Wang, e-mail: [email protected] Source of support: This study was supported by grants from National Natural Science Foundation of China (No.
    [Show full text]
  • DEFINING the FUNCTIONS of USP22 and USP44 in REGULATION of H2BUB1 LEVELS Xianjiang Lan
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2016 DEFINING THE FUNCTIONS OF USP22 AND USP44 IN REGULATION OF H2BUB1 LEVELS xianjiang Lan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry Commons, Cancer Biology Commons, Cell Biology Commons, and the Molecular Biology Commons Recommended Citation Lan, xianjiang, "DEFINING THE FUNCTIONS OF USP22 AND USP44 IN REGULATION OF H2BUB1 LEVELS" (2016). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 686. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/686 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. DEFINING THE FUNCTIONS OF USP22 AND USP44 IN REGULATION OF H2BUB1 LEVELS BY Xianjiang Lan, Ph.D. Candidate APPROVED: _____________________________________
    [Show full text]
  • Title: a Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic
    bioRxiv preprint doi: https://doi.org/10.1101/517490; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Title Page: 2 3 Title: A yeast phenomic model for the influence of Warburg metabolism on genetic 4 buffering of doxorubicin 5 6 Authors: Sean M. Santos1 and John L. Hartman IV1 7 1. University of Alabama at Birmingham, Department of Genetics, Birmingham, AL 8 Email: [email protected], [email protected] 9 Corresponding author: [email protected] 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 bioRxiv preprint doi: https://doi.org/10.1101/517490; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 26 Abstract: 27 Background: 28 Saccharomyces cerevisiae represses respiration in the presence of adequate glucose, 29 mimicking the Warburg effect, termed aerobic glycolysis. We conducted yeast phenomic 30 experiments to characterize differential doxorubicin-gene interaction, in the context of 31 respiration vs. glycolysis. The resulting systems level biology about doxorubicin 32 cytotoxicity, including the influence of the Warburg effect, was integrated with cancer 33 pharmacogenomics data to identify potentially causal correlations between differential 34 gene expression and anti-cancer efficacy.
    [Show full text]
  • Bioinformatic Gene Analysis for Potential Biomarkers And
    Zou et al. J Transl Med (2019) 17:45 https://doi.org/10.1186/s12967-019-1790-x Journal of Translational Medicine RESEARCH Open Access Bioinformatic gene analysis for potential biomarkers and therapeutic targets of atrial fbrillation-related stroke Rongjun Zou1†, Dingwen Zhang1†, Lei Lv1†, Wanting Shi2, Zijiao Song3, Bin Yi1, Bingjia Lai4, Qian Chen5, Songran Yang6,7* and Ping Hua1* Abstract Background: Atrial fbrillation (AF) is one of the most prevalent sustained arrhythmias, however, epidemiological data may understate its actual prevalence. Meanwhile, AF is considered to be a major cause of ischemic strokes due to irregular heart-rhythm, coexisting chronic vascular infammation, and renal insufciency, and blood stasis. We studied co-expressed genes to understand relationships between atrial fbrillation (AF) and stroke and reveal potential biomarkers and therapeutic targets of AF-related stroke. Methods: AF-and stroke-related diferentially expressed genes (DEGs) were identifed via bioinformatic analysis Gene Expression Omnibus (GEO) datasets GSE79768 and GSE58294, respectively. Subsequently, extensive target prediction and network analyses methods were used to assess protein–protein interaction (PPI) networks, Gene Ontology (GO) terms and pathway enrichment for DEGs, and co-expressed DEGs coupled with corresponding predicted miRNAs involved in AF and stroke were assessed as well. Results: We identifed 489, 265, 518, and 592 DEGs in left atrial specimens and cardioembolic stroke blood samples at < 3, 5, and 24 h, respectively. LRRK2, CALM1, CXCR4, TLR4, CTNNB1, and CXCR2 may be implicated in AF and the hub- genes of CD19, FGF9, SOX9, GNGT1, and NOG may be associated with stroke. Finally, co-expressed DEGs of ZNF566, PDZK1IP1, ZFHX3, and PITX2 coupled with corresponding predicted miRNAs, especially miR-27a-3p, miR-27b-3p, and miR-494-3p may be signifcantly associated with AF-related stroke.
    [Show full text]
  • W O 2019/067145 Al 04 April 2019 (04.04.2019) W IPO I PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property (1) Organization11111111111111111111111I1111111111111ii111liiili International Bureau (10) International Publication Number (43) International Publication Date W O 2019/067145 Al 04 April 2019 (04.04.2019) W IPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K47/40 (2017.01) A61K 9/08 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K9/00(2006.01) Rule 4.17: (21) International Application Number: Declarations under be granted a PCT/US2018/048414 - as to applicant's entitlement to applyfor and patent (Rule 4.17(i)) (22) International Filing Date: - as to the applicant'sentitlement to claim the priority ofthe 28 August 2018 (28.08.2018) earlier application (Rule 4.17(iii)) (25) Filing Language: English Published: (26) Publication Language: English with internationalsearch report (Art. 21(3)) (30) Priority Data: 62/565,053 28 September 2017 (28.09.2017) US 62/573,658 17 October 2017 (17.10.2017) US 62/586,826 15 November 2017 (15.11.2017) US 62/551,193 04 December 2017 (04.12.2017) US 62/643,694 15 March 2018 (15.03.2018) US 62/679,912 03 June 2018 (03.06.2018) US (71) Applicant: ASDERA LLC [US/US]; 220 E. 70th Street, #5C, New York, NY 10021 (US). (72) Inventor: WITTKOWSKI, Knut, M.; 220 E. 70th Street, #5C, New York, NY 10021 (US). (74) Agent: ZURAWSKI, John, A. et al.; BALLARD SPAHR LLP, 1735 Market Street, 51st Floor, Philadelphia, PA 19103 (US). (81) Designated States (unless
    [Show full text]
  • Mouse Usp44 Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Usp44 Knockout Project (CRISPR/Cas9) Objective: To create a Usp44 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Usp44 gene (NCBI Reference Sequence: NM_001206851 ; Ensembl: ENSMUSG00000020020 ) is located on Mouse chromosome 10. 6 exons are identified, with the ATG start codon in exon 2 and the TGA stop codon in exon 6 (Transcript: ENSMUST00000216224). Exon 2~3 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a knock-out allele exhibit chromosomal instability, aneuploidy and increased tumor incidence. Exon 2 starts from the coding region. Exon 2~3 covers 76.0% of the coding region. The size of effective KO region: ~3259 bp. The KO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 6 Legends Exon of mouse Usp44 Knockout region Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 2 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 3 is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Homo Sapiens, Homo Neanderthalensis and the Denisova Specimen: New Insights on Their Evolutionary Histories Using Whole-Genome Comparisons
    Genetics and Molecular Biology, 35, 4 (suppl), 904-911 (2012) Copyright © 2012, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Research Article Homo sapiens, Homo neanderthalensis and the Denisova specimen: New insights on their evolutionary histories using whole-genome comparisons Vanessa Rodrigues Paixão-Côrtes, Lucas Henrique Viscardi, Francisco Mauro Salzano, Tábita Hünemeier and Maria Cátira Bortolini Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Abstract After a brief review of the most recent findings in the study of human evolution, an extensive comparison of the com- plete genomes of our nearest relative, the chimpanzee (Pan troglodytes), of extant Homo sapiens, archaic Homo neanderthalensis and the Denisova specimen were made. The focus was on non-synonymous mutations, which consequently had an impact on protein levels and these changes were classified according to degree of effect. A to- tal of 10,447 non-synonymous substitutions were found in which the derived allele is fixed or nearly fixed in humans as compared to chimpanzee. Their most frequent location was on chromosome 21. Their presence was then searched in the two archaic genomes. Mutations in 381 genes would imply radical amino acid changes, with a frac- tion of these related to olfaction and other important physiological processes. Eight new alleles were identified in the Neanderthal and/or Denisova genetic pools. Four others, possibly affecting cognition, occured both in the sapiens and two other archaic genomes. The selective sweep that gave rise to Homo sapiens could, therefore, have initiated before the modern/archaic human divergence.
    [Show full text]
  • Overexpression of Ubiquitin Specific Protease 44 (USP44) Induces Chromosomal Instability and Is Frequently Observed in Human T-Cell Leukemia
    Overexpression of Ubiquitin Specific Protease 44 (USP44) Induces Chromosomal Instability and Is Frequently Observed in Human T-Cell Leukemia Ying Zhang1,2, Jan van Deursen1,2, Paul J. Galardy1,2* 1 Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States of America, 2 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States of America Abstract Cdc20-anaphase promoting complex/cyclosome (Cdc20-APC/C) E3 ubiquitin ligase activity is essential for orderly mitotic progression. The deubiqituinase USP44 was identified as a key regulator of APC/C and has been proposed to suppress Cdc20-APC/C activity by maintaining its association with the inhibitory protein Mad2 until all chromosomes are properly attached to the mitotic spindle. However, this notion has been challenged by data in which a lysine-less mutant of Cdc20 leads to premature anaphase, suggesting that it’s ubiquitination is not required for APC/C activation. To further evaluate its role in checkpoint function and chromosome instability, we studied the consequences of over-expression of mouse Usp44 in non-transformed murine embryonic fibroblasts. Here we show that cells with high Usp44 are prone to chromosome segregation errors and aneuploidization. We find that high Usp44 promotes association of Mad2 with Cdc20 and reinforces the mitotic checkpoint. Surprisingly, the APC/C-Cdc20 substrate cyclin B1 is stabilized in G2 when Usp44 is over-expressed, but is degraded with normal kinetics once cells enter mitosis. Furthermore, we show that USP44 expression is elevated in subset of T-cell leukemias. These data are consistent with an important role for USP44 in regulating Cdc20-APC/C activity and suggest that high levels of this enzyme may contribute to the pathogenesis of T-ALL.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0050728A1 Benvenisty Et Al
    US 2015.0050728A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050728A1 Benvenisty et al. (43) Pub. Date: Feb. 19, 2015 (54) IDENTIFICATION OF NOVEL CELL (60) Provisional application No. 61/536,099, filed on Sep. SURFACE MARKERS FOR PANCREATC 19, 2011, provisional application No. 61/417.364, PROGENITOR CELLS AND DEFINITE filed on Nov. 26, 2010. ENDODERMAL CELLS Publication Classification (71) Applicants: Nissim Benvenisty, Jerusalem (IL); Joseph Itskovitz-Eldor, Haifa (IL); (51) Int. Cl. Bettina Fishman, Haifa (IL); Hanna CI2N5/071 (2006.01) Segev, Doar-Na Emek Hefer (IL); (52) U.S. Cl. Danny Kitsberg, Jerusalem (IL) CPC .................................... CI2N5/0678 (2013.01) USPC .......................................................... 435/325 (72) Inventors: Nissim Benvenisty, Jerusalem (IL); Joseph Itskovitz-Eldor, Haifa (IL); (57) ABSTRACT Bettina Fishman, Haifa (IL); Hanna Segev, Doar-Na Emek Hefer (IL); Methods of identifying, isolating and qualifying pancreatic Danny Kitsberg, Jerusalem (IL) progenitor cells and definite endodermal cells. An isolated population of pancreatic progenitor cells, including at least (21) Appl. No.: 14/528,837 75% of cells having a TROP-2+ and/or TROP-2+/GPR50+ expression pattern and an isolated population of definite (22) Filed: Oct. 30, 2014 endodermal cells, including at least 50% of cells having a SOX17+/SOX7+/GSC+/CER+/FOXA2+/CXCR4+f Related U.S. Application Data NANOG expression pattern. Nucleic acid constructs includ (63) Continuation of application No. 13/903,815, filed on ing a reporter protein under the transcriptional regulation of May 28, 2013, which is a continuation of application SOX17 regulatory sequence or of PDX1 regulatory sequence, No. PCT/IB2011/055283, filed on Nov.
    [Show full text]